Cargando…

Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up

Non-selective beta-blockers are the mainstay of medical therapy for portal hypertension in liver cirrhosis. Inhibitors of phosphodiesterase-5 (PDE-5-inhibitors) reduce portal pressure in the acute setting by > 10% which may suggest a long-term beneficial effect. Currently, there is no available d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deibert, Peter, Lazaro, Adhara, Stankovic, Zoran, Schaffner, Denise, Rössle, Martin, Kreisel, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776405/ https://www.ncbi.nlm.nih.gov/pubmed/29391766 http://dx.doi.org/10.3748/wjg.v24.i3.438

Ejemplares similares

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension
por: Schaffner, Denise, et al.
Publicado: (2018)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver
por: Lazaro, Adhara, et al.
Publicado: (2023)

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
por: Bremer, Hinrich C, et al.
Publicado: (2007)

The beneficial effects of curcumin in cirrhotic rats with portal hypertension
por: Hsu, Shao-Jung, et al.
Publicado: (2017)

Comprehensive lifestyle intervention vs soy protein-based meal regimen in non-alcoholic steatohepatitis
por: Deibert, Peter, et al.
Publicado: (2019)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Idiopathic non-cirrhotic portal hypertension: a review
por: Schouten, Jeoffrey NL, et al.
Publicado: (2015)

Research progress on signaling pathways in cirrhotic portal hypertension
por: Xu, Wen, et al.
Publicado: (2018)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Non-cirrhotic portal hypertension in an ankylosing spondylitis patient
por: Park, Sukki, et al.
Publicado: (2018)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension: a case report: Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Pathological abnormalities in splenic vasculature in non-cirrhotic portal hypertension: Its relevance in the management of portal hypertension
por: Gupta, Shahana, et al.
Publicado: (2020)

Chronic Myeloid Leukemia Presenting as Non-cirrhotic Portal Hypertension
por: Gemnani, Rinkle R, et al.
Publicado: (2023)

Case Report: Assessing COVID-19 Transmission in Professional Volleyball in Germany, September to December 2020: An Epidemiological Study
por: Morath, Oliver, et al.
Publicado: (2022)

Blood Ammonia Level Correlates with Severity of Cirrhotic Portal Hypertensive Gastropathy
por: El-Kalla, Ferial, et al.
Publicado: (2018)

Systemic Mastocytosis Complicated by Non-Cirrhotic Portal Hypertension and Variceal Bleeding
por: McCarty, Thomas R., et al.
Publicado: (2017)

Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension
por: Lin, Jie, et al.
Publicado: (2018)

Interobserver study on histologic features of idiopathic non-cirrhotic portal hypertension
por: Kmeid, Michel, et al.
Publicado: (2020)

Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2021)

Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022)

Pregnancy in Patients with Non-cirrhotic Portal Hypertension: A Literature Review
por: Giri, Suprabhat, et al.
Publicado: (2022)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
por: Giorgi, Mauro, et al.
Publicado: (2020)

Association Between Portal Vein Color Doppler Findings and the Severity of Disease in Cirrhotic Patients With Portal Hypertension
por: Mittal, Puneet, et al.
Publicado: (2011)

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2019)

Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction
por: Artru, Florent, et al.
Publicado: (2022)

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension
por: Ørntoft, Nikolaj Worm, et al.
Publicado: (2021)

Phlebosclerotic Colitis in a Cirrhotic Patient with Portal Hypertension: The First Case in Korea
por: Kang, Ha Yan, et al.
Publicado: (2009)

A Case of Non-Cirrhotic Portal Hypertension Associated With Chronic Didanosine Therapy
por: Stotts, Matthew, et al.
Publicado: (2015)

Carvedilol—NSBB of Choice in All Cirrhotics? Short Title: Carvedilol for Portal Hypertension
por: Tandon, Puneeta, et al.
Publicado: (2015)

Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients
por: Chu, Haibo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_017ckf4os8b1gv07d0fhbiakjp